Russell Investments Group Ltd. lowered its stake in Repligen Co. (NASDAQ:RGEN) by 18.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 122,816 shares of the biotechnology company’s stock after selling 27,885 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.36% of Repligen worth $4,706,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of RGEN. Teachers Advisors LLC increased its stake in Repligen by 2.4% in the 1st quarter. Teachers Advisors LLC now owns 58,081 shares of the biotechnology company’s stock worth $2,044,000 after purchasing an additional 1,386 shares in the last quarter. US Bancorp DE increased its stake in Repligen by 1.2% in the 2nd quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 54 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Repligen by 4.7% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,050 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 360 shares in the last quarter. Great West Life Assurance Co. Can grew its stake in Repligen by 10.2% during the 2nd quarter. Great West Life Assurance Co. Can now owns 53,333 shares of the biotechnology company’s stock valued at $2,210,000 after acquiring an additional 4,930 shares in the last quarter. Finally, Texas Permanent School Fund grew its stake in Repligen by 9.7% during the 2nd quarter. Texas Permanent School Fund now owns 26,889 shares of the biotechnology company’s stock valued at $1,114,000 after acquiring an additional 2,385 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have weighed in on RGEN. Citigroup began coverage on Repligen in a research note on Friday, December 8th. They set a “buy” rating and a $45.00 target price on the stock. J P Morgan Chase & Co began coverage on Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price on the stock. Stephens reaffirmed an “overweight” rating and set a $50.00 target price on shares of Repligen in a research note on Tuesday, September 26th. First Analysis raised Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 target price on the stock in a research note on Monday, October 2nd. Finally, Zacks Investment Research cut Repligen from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.38.
Repligen Co. (NASDAQ:RGEN) opened at $35.36 on Thursday. Repligen Co. has a 12 month low of $28.48 and a 12 month high of $46.81. The firm has a market capitalization of $1,540.03, a PE ratio of 60.95, a price-to-earnings-growth ratio of 2.31 and a beta of 1.04.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The firm’s revenue was up 48.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.08 EPS. sell-side analysts predict that Repligen Co. will post 0.61 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/14/russell-investments-group-ltd-has-4-71-million-position-in-repligen-co-rgen.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.